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opulation pharmacokinetics of meropenem in pediatric
atients: a concurrent analysis of the plasma and urine
oncentration data
. Ikawa ∗, N. Morikawa, K. Ikeda, M. Miki, M. Kobayashi
Hiroshima University, Hiroshima, Japan
Background: This study aimed to develop a population
harmacokinetic model for meropenem in Japanese pedi-
tric patients, speciﬁcally focusing on the drug urinary
xcretion process. This study also aimed to use this model
o assess the pharmacodynamics of meropenem regimens
gainst common bacterial populations.
Methods: Pharmacokinetic data (229 plasma samples and
1 urine samples) were collected from 40 infected children
age, 0.2—14.8 years; body weight, 3.8—64.0 kg) in nine
eparate studies. The data were concurrently ﬁtted into
multi-compartment model using the NONMEM program.
he developed model was then used for a pharmacody-
amic Monte Carlo simulation to estimate the probabilities
f attaining the bactericidal target (40% of the time for
hich the free drug concentration remains above the MIC
or the bacterium).
Results: In the ﬁnal population pharmacokinetic model,
ody weight (BW, kg) was the most signiﬁcant covariate
s follows: CLr (L/h) = 0.254 3 BW, CLnr (L/h) = 3.45, Vc
L) = 0.272 3 BW, Q (L/h) = 1.65 and Vp (L) = 0.228 3 BW,
here CLr and CLnr are the renal and non-renal clearances,
p and Vc are the volumes of distribution of the central and
eripheral compartments, and Q is the intercompartmen-
al (central—peripheral) clearance. The pharmacodynamic
ssessment based on this model showed that regimens of
0—40mg/kg, three times a day (0.5-h infusions), achieved
target attainment probability of >80% against clinical
solates of Escherichia coli (MIC90 = 0.03mg/L), Streptococ-
us pneumoniae (MIC90 = 0.5mg/L), methicillin-susceptible
taphylococcus aureus (MIC90 = 0.12mg/L), Haemophilus
nﬂuenzae (MIC90 = 0.25mg/L) and Pseudomonas aeruginosa
MIC90 = 1mg/L), in most typical patients (BW = 10, 20 and
0 kg).
Conclusion: These results provide a better understand-
ng of the pharmacokinetics of meropenem in Japanese
ediatric patients. They are also useful in the choice of a
eropenem regimen based on the BW of the patient and
he susceptibility of the causative bacteria.
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ppropriate use of ﬂuoroquinolones in a Lebanese ter-
iary medical center
. Kabbara ∗, P. Rahbany, S. Al-Natour
Lebanese American University, Byblos, Lebanon
Background: Fluoroquinolones are among themost widely
rescribed antibiotics especially for respiratory and urinary
ract infections. However, concerns about increasing resis-
ant micro-organisms associated with the use of these agents
ave emerged in both community and hospital settings. This
as been particularly a rising major problem in Lebanon
s the resistance to ﬂuoroquinolones has reached 30-40%
y 2008 (for E.coli and Klebsiella species). The primary
bjective of this study is to assess the appropriate use of
uoroquionolones in a Lebanese tertiary medical center by
valuating the appropriate indication, dose, dosage adjust-
ent in renal impairment, and the duration of treatment.
Methods: We conducted a prospective observational
tudy at Raﬁc Harriri University Hospital in Beirut, Lebanon
etween January and June 2009. We identiﬁed 118 patients
eceiving broad spectrum ﬂuoroquinolones (levoﬂoxacin,
iproﬂoxacin and moxiﬂoxacin). The majority of patients
ere in internal medicine ﬂoors or in the intensive care unit.
data collection form inculding all pertinent information
as used. Patients were followed from initiation of ﬂuoro-
uinolone therapy to the discharge date. The assessment
or the appropriate use was based on relevant guidelines
rom the Infectious Disease Society of America, manufac-
urer package inserts and clinical judgment. Monitoring of
lood glucose levels with ﬂuoroquinolone therapy was also
valuated.
Results: The patient population was predominantly male
62.7%) and the mean age was 62.8 years. About one third
f the patients (29.6%) had decreased renal function neces-
itating dosage adjustment of ciproﬂoxacin or levoﬂoxacin.
he main indications were community acquired pneumonia
nd diabetic foot infections. Cultures were taken in only
9.3% of patients. Of the positive cultures, the most com-
on isolated micro-organisms were E. coli and Pseudomonas
eruginosa. The ﬁnal percentage of ﬂuoroquinolone appro-
riate indication, dose and duration of therapy was 93.2%,
4.5% and 57.6% respectively (which were also calculated
or each drug separately). 57.1% of patients did not receive
he appropriate dose adjustment according to the level of
enal dysfunction (calculated by using Cockcroft-Gault equa-
ion). Baseline blood glucose was monitored in only 21.5% of
atients.
Conclusion: The major clinical interventions that need
mprovement in our tertiary medical center are adequate
enal adjustment of the dose of ﬂuoroquinolones and the
uration of therapy.
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